Step 1 topics → Microbiology → Antifungals

Antifungals

USMLE Step 1 trap: Confuses amphotericin B's mechanism (ergosterol binding/pore formation) with azole mechanism (ergosterol synthesis inhibition). Amphotericin B binds directly to ergosterol in the fungal membrane, forming pores that cause leakage of intracellular contents; azoles inhibit ergosterol synthesis.

Antifungals are a high-yield pharmacology topic on USMLE Step 1 because they test three distinct mechanisms hitting three distinct fungal targets — and the exam loves to mix them up. The three main classes are polyenes (amphotericin B, nystatin), azoles (fluconazole, voriconazole, itraconazole), and echinocandins (caspofungin, micafungin) — each with a different target, different clinical niche, and different toxicity profile. The exam will present vignettes of immunocompromised patients (HIV, transplant, neutropenic) with fungal infections and ask you to identify the right drug, or give you a mechanism description and ask which class it matches.

The biggest trap students fall into is blurring the line between amphotericin B and azoles — both involve ergosterol, but in completely different ways. Amphotericin B binds ergosterol directly and punches holes in the membrane; azoles block ergosterol synthesis upstream. Students who mix these up will confidently answer wrong on mechanism questions. The second trap is thinking fluconazole covers everything — it does not cover Aspergillus, and confusing it with voriconazole on an aspergillosis vignette is a classic Step 1 mistake.

Toxicity is tested just as hard as mechanism. Amphotericin B's nephrotoxicity is famous, but the exam specifically targets the downstream electrolyte consequences — hypokalemia and hypomagnesemia from renal tubular damage — and whether you know that liposomal amphotericin reduces kidney damage without losing efficacy. Azoles inhibit human CYP450 too, which creates drug-drug interactions the exam likes to probe. Keep all three classes straight and you'll clean up this section.

From real student decks
70%have cards covering this topic
54%have mature cards
1.0median lapses in 14 days

Common misconceptions

Common mistake
Wrong: Amphotericin B inhibits ergosterol synthesis.
Right: Amphotericin B binds directly to ergosterol in the fungal membrane, forming pores that cause leakage of intracellular contents; azoles inhibit ergosterol synthesis.
Both amphotericin B and azoles involve ergosterol, which is why students conflate them — but the mechanism is completely different. Amphotericin B binds ergosterol that is already in the fungal membrane, physically inserting into it and forming pores that leak ions and kill the cell. Azoles never touch existing ergosterol; they block the enzyme that synthesizes new ergosterol. The key mental model: amphotericin B = direct membrane binding and destruction; azoles = upstream synthesis blockade.
Common mistake
Gap: Misses the electrolyte disturbances (hypokalemia, hypomagnesemia) associated with amphotericin B nephrotoxicity
Amphotericin B causes significant nephrotoxicity (azotemia, renal tubular acidosis, hypokalemia, hypomagnesemia); liposomal formulations reduce nephrotoxicity while maintaining efficacy.
Students remember 'amphotericin B causes kidney damage' but miss the downstream consequences the exam specifically tests. When amphotericin B damages the renal tubules, it causes wasting of both potassium and magnesium — so patients develop hypokalemia and hypomagnesemia that must be repleted. Liposomal amphotericin B encapsulates the drug in a lipid shell so it delivers preferentially to fungal-infected tissues with much less renal tubular exposure, reducing nephrotoxicity without losing fungal killing.
Common mistake
Wrong: Azoles directly disrupt the fungal cell membrane by binding ergosterol.
Right: Azoles inhibit fungal CYP450 enzyme lanosterol 14-alpha-demethylase, blocking ergosterol synthesis and depleting membrane ergosterol.
Azoles do not touch the fungal membrane directly — they work entirely upstream in the biosynthetic pathway. They inhibit lanosterol 14-alpha-demethylase, a fungal CYP450 enzyme required to convert lanosterol to ergosterol. Without ergosterol, the membrane loses integrity, but this is a metabolic depletion effect, not direct binding. This distinction matters clinically because azoles also partially inhibit human CYP450 enzymes, creating drug-drug interactions — a consequence that makes no sense if you think azoles just bind membranes.
Common mistake
Wrong: Echinocandins target the fungal cell membrane like polyenes.
Right: Echinocandins inhibit beta-1,3-glucan synthase, disrupting fungal cell wall synthesis; they do not target the cell membrane.
Echinocandins target the fungal cell wall, not the cell membrane — these are not the same structure and the distinction is testable. They inhibit beta-1,3-glucan synthase, the enzyme that polymerizes glucan into the fungal cell wall. Without the glucan scaffold, the wall loses integrity and the cell lyses osmotically. This is analogous to how beta-lactams target bacterial cell wall synthesis — a useful mnemonic since fungi have walls but bacteria targeted by beta-lactams have peptidoglycan while fungi have glucan.
Common mistake
Wrong: Fluconazole is effective against Aspergillus species.
Right: Fluconazole has no activity against Aspergillus; voriconazole (or amphotericin B) is the treatment of choice for invasive aspergillosis.
Fluconazole has an unusually narrow azole spectrum — it covers Candida and Cryptococcus but has zero activity against Aspergillus. This is because Aspergillus has innate resistance to fluconazole due to differences in its CYP450 enzyme target. On USMLE Step 1, an immunocompromised patient with pulmonary infiltrates or sinusitis and hyphal elements on biopsy needs voriconazole (first-line) or amphotericin B — reaching for fluconazole here is the wrong answer and represents a high-frequency mistake.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Given a description of a drug that binds ergosterol and forms membrane pores causing leakage of intracellular contents, identify it as amphotericin B (a polyene) and distinguish this mechanism from azoles that block ergosterol synthesis
  2. Recognize the full toxicity profile of amphotericin B including nephrotoxicity, azotemia, renal tubular acidosis, hypokalemia, and hypomagnesemia — and know that liposomal formulations reduce nephrotoxicity while preserving antifungal activity
  3. Explain how azoles work by inhibiting the fungal CYP450 enzyme lanosterol 14-alpha-demethylase, blocking ergosterol synthesis upstream — and apply this to why azoles also cause human CYP450 drug interactions
  4. Match specific azoles to their clinical indications: fluconazole for Candida and Cryptococcal meningitis (maintenance), voriconazole as first-line for invasive Aspergillus, itraconazole for endemic dimorphic fungi
  5. Identify that fluconazole has no activity against Aspergillus and that voriconazole (or amphotericin B) is required for invasive aspergillosis — a classic USMLE Step 1 clinical application question
  6. Distinguish echinocandins (caspofungin, micafungin) as cell wall agents that inhibit beta-1,3-glucan synthase, separate from polyenes and azoles which target the cell membrane or membrane synthesis

Can you avoid these mistakes?

A patient with HIV and CD4 count of 40 develops fever and headache. CSF shows Cryptococcus neoformans. After induction therapy, you plan long-term maintenance. Which antifungal do you use for maintenance, and why would you NOT use it for initial induction of severe disease?
A neutropenic patient post-chemotherapy develops sinusitis with black eschar and tissue invasion on imaging. Biopsy shows septate hyphae with acute-angle branching consistent with Aspergillus. A medical student suggests fluconazole. What is wrong with this suggestion, and what is the correct treatment?
Amphotericin B and azoles both 'target ergosterol' — explain in one or two sentences how their mechanisms are fundamentally different, and identify which class is more likely to cause drug-drug interactions with warfarin and why.
A patient starting amphotericin B for disseminated histoplasmosis develops rising creatinine. The team switches to liposomal amphotericin B. Two days later labs show potassium of 2.9 mEq/L and magnesium of 1.1 mg/dL. Explain the mechanism behind both the electrolyte abnormalities and why the liposomal formulation was chosen.

Related topics

Bacterial Staining and Structure Bacterial Culture Requirements Encapsulated Organisms Bacterial Exotoxins

See how your Anki deck covers this topic.

Upload your deck for a free audit →